Nothing Special   »   [go: up one dir, main page]

Westcott et al., 2023 - Google Patents

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity

Westcott et al., 2023

View HTML
Document ID
6695978053876819262
Author
Westcott P
Muyas F
Hauck H
Smith O
Sacks N
Ely Z
Jaeger A
Rideout III W
Zhang D
Bhutkar A
Beytagh M
Canner D
Jaramillo G
Bronson R
Naranjo S
Jin A
Patten J
Cruz A
Shanahan S
Cortes-Ciriano I
Jacks T
Publication year
Publication venue
Nature Genetics

External Links

Snippet

DNA mismatch repair deficiency (MMRd) is associated with a high tumor mutational burden (TMB) and sensitivity to immune checkpoint blockade (ICB) therapy. Nevertheless, most MMRd tumors do not durably respond to ICB and critical questions remain about …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Similar Documents

Publication Publication Date Title
Westcott et al. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity
Westcott et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
Germano et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Samstein et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Jia et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer
Newey et al. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment
Decarvalho et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma
George et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma
Smith et al. Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes
Leisegang et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation
Delfau-Larue et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Capdevila et al. Early evolutionary divergence between papillary and anaplastic thyroid cancers
Li et al. A bioinformatics workflow for variant peptide detection in shotgun proteomics
Istaces et al. EOMES interacts with RUNX3 and BRG1 to promote innate memory cell formation through epigenetic reprogramming
CN103608033B (en) For the individuation vaccine of cancer
AU2015358387B2 (en) Identification, selection and use of high curative potential T cell epitopes
Schneeberger et al. Quantitation of murine stroma and selective purification of the human tumor component of patient-derived xenografts for genomic analysis
AU2016319316A1 (en) "immune checkpoint intervention" in cancer
Chou et al. Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice
Ji et al. Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing
US20190189241A1 (en) Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy
Morinaga et al. Mixed response to cancer immunotherapy is driven by intratumor heterogeneity and differential interlesion immune infiltration
Westcott et al. Mismatch repair deficiency is not sufficient to increase tumor immunogenicity
Patel et al. A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells
Bräunlein et al. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma